Indivior PLC (INDV) Raises 2025 Guidance After Q2 Revenue Hits $302M

We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Indivior PLC is one of them.

Indivior PLC (NASDAQ:INDV) is a pharmaceutical company specializing in treatments for opioid use disorder (OUD), with its core products SUBLOCADE, a once-monthly buprenorphine injection, and SUBOXONE film forming the backbone of its revenue.

In September 2025, the corporation reported strong Q2 results, with total net revenue of $302 million. SUBLOCADE sales rose 9% year-over-year to $209 million, driven by a 20% increase in U.S. volumes versus Q1 2025. The company subsequently raised its full-year 2025 revenue guidance to $1.03–$1.08 billion, up from $955 million–$1.025 billion, while adjusted EBITDA guidance increased to $275–$300 million, positioning Indivior among the best performing stocks in its sector.

These results reflect progress on the “Indivior Action Agenda,” a strategic initiative focused on expanding SUBLOCADE in the U.S. and streamlining operations to boost efficiency and cash generation. The company also consolidated its stock listing to Nasdaq in July 2025, emphasizing a U.S.-focused growth strategy. Strengthening commercial leadership, Patrick Barry joined as Chief Commercial Officer in May, bringing over 30 years of pharmaceutical experience to accelerate SUBLOCADE commercialization.

Indivior PLC (INDV) Raises 2025 Guidance After Q2 Revenue Hits $302M

Looking ahead, Indivior PLC (NASDAQ:INDV) expects continued SUBLOCADE growth through 2026 and beyond, alongside operational improvements that enhance shareholder value. The company is progressing toward resolving litigation settlement liabilities by 2027, which will improve financial flexibility. Research and development remain active, with pipeline programs INDV-2000 and INDV-6001 targeting next-generation treatments for OUD and related conditions.

While we acknowledge the risk and potential of INDV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INDV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.